| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.26B | 9.38 | 67 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 692.99M | 4.09 | 10.76 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 932.87M | 2.35 | -1.84 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 630.68M | 8.04 | -2.62 | -117.82% | 0.18 | |||
| IMNMImmunome, Inc. | 2.22B | 20.14 | -4.03 | -35.5% | -23.01% | -84.4% | 0.03 | |
| NKTRNektar Therapeutics | 744.1M | 36.58 | -4.21 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IBRXImmunityBio, Inc. | 2.78B | 2.82 | -4.55 | 22.71% | -422.28% | |||
| CRVSCorvus Pharmaceuticals, Inc. | 485.43M | 6.50 | -6.37 | -21.01% | 0.03 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 59.73M | 51.74M | 38.42M | 42.74M | 42.72M | 61.88M | 67.77M | 153.73M | 62.04M |
| Revenue Growth % | - | -0.13% | -0.26% | 0.11% | -0% | 0.45% | 0.1% | 1.27% | -0.6% |
| Cost of Goods Sold | 43.55M | 51.9M | 54.26M | 0 | 76.96M | 9.77M | 8.29M | 6.82M | 7.22M |
| COGS % of Revenue | 0.73% | 1% | 1.41% | - | 1.8% | 0.16% | 0.12% | 0.04% | 0.12% |
| Gross Profit | 16.18M | -156K | -15.84M | 42.74M | -34.24M | 52.11M | 59.48M | 146.91M | 54.83M |
| Gross Margin % | 0.27% | -0% | -0.41% | 1% | -0.8% | 0.84% | 0.88% | 0.96% | 0.88% |
| Gross Profit Growth % | - | -1.01% | -100.56% | 3.7% | -1.8% | 2.52% | 0.14% | 1.47% | -0.63% |
| Operating Expenses | 58.37M | 71.01M | 75.64M | 98.2M | 36.82M | 150.63M | 188.43M | 236.19M | 293.28M |
| OpEx % of Revenue | 0.98% | 1.37% | 1.97% | 2.3% | 0.86% | 2.43% | 2.78% | 1.54% | 4.73% |
| Selling, General & Admin | 14.82M | 16.37M | 21.38M | 32.59M | 36.82M | 56M | 59.54M | 62.58M | 48.45M |
| SG&A % of Revenue | 0.25% | 0.32% | 0.56% | 0.76% | 0.86% | 0.91% | 0.88% | 0.41% | 0.78% |
| Research & Development | 43.55M | 54.64M | 54.26M | 65.61M | 76.96M | 104.4M | 137.17M | 180.43M | 252.04M |
| R&D % of Revenue | 0.73% | 1.06% | 1.41% | 1.54% | 1.8% | 1.69% | 2.02% | 1.17% | 4.06% |
| Other Operating Expenses | 87K | -77K | 1.91M | 0 | -76.96M | -9.77M | -8.29M | -6.82M | -7.22M |
| Operating Income | 1.36M | -19.27M | -37.22M | -55.47M | -71.06M | -98.52M | -128.94M | -89.28M | -238.45M |
| Operating Margin % | 0.02% | -0.37% | -0.97% | -1.3% | -1.66% | -1.59% | -1.9% | -0.58% | -3.84% |
| Operating Income Growth % | - | -15.13% | -0.93% | -0.49% | -0.28% | -0.39% | -0.31% | 0.31% | -1.67% |
| EBITDA | 7.03M | -14.28M | -32.68M | -50.69M | -66.76M | -93.68M | -120.66M | -82.46M | -231.24M |
| EBITDA Margin % | 0.12% | -0.28% | -0.85% | -1.19% | -1.56% | -1.51% | -1.78% | -0.54% | -3.73% |
| EBITDA Growth % | - | -3.03% | -1.29% | -0.55% | -0.32% | -0.4% | -0.29% | 0.32% | -1.8% |
| D&A (Non-Cash Add-back) | 5.66M | 4.99M | 4.54M | 4.78M | 4.3M | 4.84M | 8.29M | 6.82M | 7.22M |
| EBIT | 1.36M | -19.08M | -37.22M | -51.39M | -28.05M | -102.4M | -113.36M | -74.73M | -187.67M |
| Net Interest Income | 251K | -416K | 16K | -276K | -2.47M | -2.56M | 109K | -9.24M | 13.36M |
| Interest Income | 251K | 273K | 1.62M | 4.07M | 1.51M | 577K | 3.46M | 14.51M | 44.42M |
| Interest Expense | 0 | 689K | 1.6M | 4.35M | 3.97M | 3.14M | 3.35M | 23.75M | 31.07M |
| Other Income/Expense | 338K | -416K | 1.91M | -276K | 38.93M | -7.01M | 12.24M | 677K | 13.36M |
| Pretax Income | 1.7M | -19.69M | -35.32M | -55.74M | -32.13M | -105.54M | -116.7M | -88.6M | -225.1M |
| Pretax Margin % | 0.03% | -0.38% | -0.92% | -1.3% | -0.75% | -1.71% | -1.72% | -0.58% | -3.63% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 2.5M | 18.19M | 2.36M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1.02% | 1.21% | 1.01% |
| Net Income | 1.7M | -19.69M | -35.32M | -55.74M | -32.13M | -105.54M | -119.2M | -106.79M | -227.46M |
| Net Margin % | 0.03% | -0.38% | -0.92% | -1.3% | -0.75% | -1.71% | -1.76% | -0.69% | -3.67% |
| Net Income Growth % | - | -12.57% | -0.79% | -0.58% | 0.42% | -2.28% | -0.13% | 0.1% | -1.13% |
| Net Income (Continuing) | 1.7M | -19.69M | -35.32M | -55.74M | -32.13M | -105.54M | -119.2M | -106.79M | -227.46M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 3.86 | -2.81 | -1.54 | -2.43 | -0.99 | -2.29 | -2.35 | -1.78 | -2.96 |
| EPS Growth % | - | -1.73% | 0.45% | -0.58% | 0.59% | -1.31% | -0.03% | 0.24% | -0.66% |
| EPS (Basic) | 3.86 | -2.81 | -1.55 | -2.43 | -0.99 | -2.29 | -2.35 | -1.78 | -2.96 |
| Diluted Shares Outstanding | 441.2K | 7M | 22.87M | 22.96M | 32.57M | 46.12M | 50.74M | 60.16M | 76.83M |
| Basic Shares Outstanding | 441.2K | 7M | 22.86M | 22.96M | 32.57M | 46.12M | 50.74M | 60.16M | 76.83M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 49.69M | 25.63M | 209.95M | 128.57M | 378.18M | 218.51M | 353.15M | 421.54M | 343.31M |
| Cash & Short-Term Investments | 47.52M | 22.02M | 204.49M | 117.86M | 368.14M | 197.94M | 334.36M | 375.62M | 316.89M |
| Cash Only | 11.59M | 22.02M | 125.3M | 4.96M | 206.15M | 30.41M | 47.25M | 69.27M | 190.3M |
| Short-Term Investments | 35.93M | 0 | 79.19M | 112.9M | 161.99M | 167.52M | 287.11M | 306.35M | 126.59M |
| Accounts Receivable | 577K | 1.62M | 2.49M | 6.3M | 5.56M | 12.45M | 7.12M | 36.08M | 8.62M |
| Days Sales Outstanding | 3.53 | 11.46 | 23.65 | 53.79 | 47.49 | 73.46 | 38.36 | 85.66 | 50.69 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 2.96M | 4.41M | 0 | 0 | 11.67M | 9.85M | 17.8M |
| Total Non-Current Assets | 19.59M | 15.14M | 13.19M | 27.8M | 15.93M | 122.89M | 53.79M | 49.19M | 43.9M |
| Property, Plant & Equipment | 18.69M | 14M | 10.93M | 9.63M | 12.94M | 51.59M | 51.06M | 44.76M | 35.87M |
| Fixed Asset Turnover | 3.20x | 3.70x | 3.51x | 4.44x | 3.30x | 1.20x | 1.33x | 3.43x | 1.73x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 482K | 223K | 15K | 15.62M | 0 | 68.78M | -32.02M | 0 | 0 |
| Other Non-Current Assets | 417K | 920K | 2.24M | 2.54M | 2.99M | 2.53M | 34.75M | 4.44M | 8.03M |
| Total Assets | 69.28M | 40.77M | 223.14M | 156.37M | 394.11M | 341.41M | 406.94M | 470.74M | 387.21M |
| Asset Turnover | 0.86x | 1.27x | 0.17x | 0.27x | 0.11x | 0.18x | 0.17x | 0.33x | 0.16x |
| Asset Growth % | - | -0.41% | 4.47% | -0.3% | 1.52% | -0.13% | 0.19% | 0.16% | -0.18% |
| Total Current Liabilities | 50.18M | 31.96M | 36.42M | 32.97M | 29.6M | 41.74M | 66.55M | 93.75M | 131.89M |
| Accounts Payable | 3.39M | 2.9M | 3.06M | 5.58M | 5.54M | 6.01M | 4.8M | 9.44M | 10.47M |
| Days Payables Outstanding | 28.45 | 20.41 | 20.59 | - | 26.29 | 224.42 | 211.26 | 505.52 | 529.7 |
| Short-Term Debt | 0 | 14.56M | 4.72M | 1M | 0 | 9.38M | 17.09M | 4.06M | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 22K | 143K | 7.06M | 901K | 627K | 11.42M | 11.64M | 18.58M | 16.91M |
| Current Ratio | 0.99x | 0.80x | 5.76x | 3.90x | 12.78x | 5.24x | 5.31x | 4.50x | 2.60x |
| Quick Ratio | 0.99x | 0.80x | 5.76x | 3.90x | 12.78x | 5.24x | 5.31x | 4.50x | 2.60x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 110M | 117.81M | 55.18M | 25.61M | 32.47M | 47.11M | 123.35M | 227.34M | 210.71M |
| Long-Term Debt | 0 | 0 | 10M | 8.88M | 24.55M | 15.74M | 3.77M | 0 | 180.81M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 31.22M | 29.57M | 23.15M | 15.67M |
| Deferred Tax Liabilities | -1.19M | 0 | 476K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 104.14M | 104.66M | 578K | 543K | 1.82M | 146K | 119K | 1.69M | 1.69M |
| Total Liabilities | 160.18M | 149.77M | 91.6M | 58.58M | 62.06M | 88.84M | 189.9M | 321.09M | 342.61M |
| Total Debt | 1.19M | 14.63M | 14.72M | 9.88M | 24.55M | 57.37M | 55.02M | 33.63M | 203.96M |
| Net Debt | -10.4M | -7.39M | -110.57M | 4.92M | -181.61M | 26.96M | 7.76M | -35.63M | 13.66M |
| Debt / Equity | - | - | 0.11x | 0.10x | 0.07x | 0.23x | 0.25x | 0.22x | 4.57x |
| Debt / EBITDA | 0.17x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -1.48x | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -27.97x | -23.26x | -12.75x | -17.88x | -31.41x | -38.54x | -3.76x | -7.67x |
| Total Equity | -90.9M | -109M | 131.54M | 97.79M | 332.05M | 252.56M | 217.05M | 149.65M | 44.6M |
| Equity Growth % | - | -0.2% | 2.21% | -0.26% | 2.4% | -0.24% | -0.14% | -0.31% | -0.7% |
| Book Value per Share | -206.03 | -15.58 | 5.75 | 4.26 | 10.19 | 5.48 | 4.28 | 2.49 | 0.58 |
| Total Shareholders' Equity | -90.9M | -109M | 131.54M | 97.79M | 332.05M | 252.56M | 217.05M | 149.65M | 44.6M |
| Common Stock | 16K | 0 | 23K | 23K | 46K | 46K | 58K | 61K | 83K |
| Retained Earnings | -95.32M | -115.01M | -150.33M | -195.75M | -227.87M | -333.41M | -452.62M | -559.41M | -786.87M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -17K | -208K | -47K | 165K | 129K | -314K | -618K | 21K | 39K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -13.15M | -37.07M | 12.68M | -65.02M | -67.8M | -81.68M | 3.55M | -111.62M | -191.54M |
| Operating CF Margin % | -0.22% | -0.72% | 0.33% | -1.52% | -1.59% | -1.32% | 0.05% | -0.73% | -3.09% |
| Operating CF Growth % | - | -1.82% | 1.34% | -6.13% | -0.04% | -0.2% | 1.04% | -32.45% | -0.72% |
| Net Income | 1.7M | -19.69M | -35.32M | -55.74M | -32.13M | -105.54M | -119.2M | -106.79M | -227.46M |
| Depreciation & Amortization | 5.66M | 4.99M | 4.54M | 4.78M | 4.3M | 4.84M | 5.69M | 6.82M | 7.22M |
| Stock-Based Compensation | 968K | 1.39M | 2.87M | 10.31M | 11.92M | 23.24M | 26.3M | 24.91M | 24.69M |
| Deferred Taxes | 80K | 3M | -1.5M | -1.3M | -41.01M | 7.24M | 0 | 0 | 0 |
| Other Non-Cash Items | 98K | 132K | -517K | 193K | 606K | 6.16M | -13.65M | -2.17M | -4.88M |
| Working Capital Changes | -21.66M | -26.9M | 42.61M | -23.26M | -11.49M | -17.62M | 104.41M | -34.38M | 8.9M |
| Change in Receivables | -171K | -1.05M | -865K | -3.81M | 739K | -6.89M | 5.34M | -28.96M | 27.46M |
| Change in Inventory | -389K | -354K | -1.67M | -1.25M | -58K | -4.54M | 0 | 0 | 0 |
| Change in Payables | 874K | -473K | 209K | 2.25M | -947K | 6.43M | -1.23M | 4.81M | 706K |
| Cash from Investing | 9.59M | 32.6M | -80.19M | -51.13M | 604K | -97.31M | -35.02M | -3.92M | 218.51M |
| Capital Expenditures | -4.39M | -3.32M | -1.56M | -3.48M | -7.13M | -15.32M | -7.86M | -4.32M | -3.1M |
| CapEx % of Revenue | 0.07% | 0.06% | 0.04% | 0.08% | 0.17% | 0.25% | 0.12% | 0.03% | 0.05% |
| Acquisitions | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 16K | 80K | 80K | -47.65M | 89K | 9K | -28.73M | 0 | 0 |
| Cash from Financing | 177K | 14.64M | 170.78M | -4.18M | 269.25M | 3.26M | 48.31M | 137.55M | 94.05M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - |
| Other Financing | 177K | -362K | 1.61M | -297K | 2.83M | 4.25M | 1.42M | 138.08M | 1.61M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -17.55M | -40.39M | 11.13M | -68.5M | -74.93M | -97M | -4.31M | -115.93M | -194.64M |
| FCF Margin % | -0.29% | -0.78% | 0.29% | -1.6% | -1.75% | -1.57% | -0.06% | -0.75% | -3.14% |
| FCF Growth % | - | -1.3% | 1.28% | -7.16% | -0.09% | -0.29% | 0.96% | -25.9% | -0.68% |
| FCF per Share | -39.77 | -5.77 | 0.49 | -2.98 | -2.30 | -2.10 | -0.08 | -1.93 | -2.53 |
| FCF Conversion (FCF/Net Income) | -7.73x | 1.88x | -0.36x | 1.17x | 2.11x | 0.77x | -0.03x | 1.05x | 0.84x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 2.05M | 0 | 1.13M | 310K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 103K | 0 | 379K | 17.52M |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -313.4% | -48.62% | -14.95% | -36.11% | -50.77% | -58.25% | -234.19% |
| Return on Invested Capital (ROIC) | - | - | - | -67.28% | -42.1% | -34.37% | -38.35% | -39.52% | -207.62% |
| Gross Margin | 27.09% | -0.3% | -41.24% | 100% | -80.14% | 84.21% | 87.77% | 95.57% | 88.37% |
| Net Margin | 2.85% | -38.05% | -91.93% | -130.44% | -75.2% | -170.55% | -175.89% | -69.47% | -366.62% |
| Debt / Equity | - | - | 0.11x | 0.10x | 0.07x | 0.23x | 0.25x | 0.22x | 4.57x |
| Interest Coverage | - | -27.97x | -23.26x | -12.75x | -17.88x | -31.41x | -38.54x | -3.76x | -7.67x |
| FCF Conversion | -7.73x | 1.88x | -0.36x | 1.17x | 2.11x | 0.77x | -0.03x | 1.05x | 0.84x |
| Revenue Growth | - | -13.38% | -25.75% | 11.24% | -0.03% | 44.84% | 9.52% | 126.84% | -59.64% |
| 2018 | 2024 | |
|---|---|---|
| Research and Development Services | - | 174K |
| Research and Development Services Growth | - | - |
| Collaboration Revenue | 13.54M | - |
| Collaboration Revenue Growth | - | - |
| Other Revenue | 5.42M | - |
| Other Revenue Growth | - | - |
Sutro Biopharma, Inc. (STRO) reported $105.6M in revenue for fiscal year 2024. This represents a 77% increase from $59.7M in 2016.
Sutro Biopharma, Inc. (STRO) saw revenue decline by 59.6% over the past year.
Sutro Biopharma, Inc. (STRO) reported a net loss of $216.8M for fiscal year 2024.
Sutro Biopharma, Inc. (STRO) has a return on equity (ROE) of -234.2%. Negative ROE indicates the company is unprofitable.
Sutro Biopharma, Inc. (STRO) had negative free cash flow of $225.1M in fiscal year 2024, likely due to heavy capital investments.